4D pharma will present preclinical data on its neurodegenerative disorders programme targeting Parkinson’s disease at each of the following healthcare conferences:

  • Neuro4D conference, May 13-14 in Frankfurt, Germany: a poster on preclinical data for MRx0005 and MRx0029 will be presented on Tuesday, May 14th

  • Keystone Symposium: Neurodegenerative Diseases: New Insights and Therapeutic Opportunities, June 16 -19 in Colorado, USA: a poster and talk on MRx0005 and MRx0029 will be given on Wednesday, June 19th

The data presented will also include a talk entitled:

“From Screening to Pre-Clinical Efficacy of Microbiome-Derived Bacterial Strains that Modulate Neuroinflammatory and Neurodegenerative Processes in Parkinson's Disease”.

The posters will be available under the “Posters and publications” section of 4D’s website as the presentations take place.